Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=-program_reference_codes
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_reference_codes", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=-program_reference_codes", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=-program_reference_codes", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=-program_reference_codes" }, "data": [ { "type": "Grant", "id": "10684", "attributes": { "award_id": "1R41AG079736-01", "title": "Jigsawdio: an AudioVisual Jigsaw Puzzle for People with Alzheimer's Disease and Alzheimer's-Disease-Related Dementias", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 20585, "first_name": "Dana Jeffrey", "last_name": "Plude", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-15", "end_date": "2023-08-31", "award_amount": 499670, "principal_investigator": { "id": 26739, "first_name": "Amy", "last_name": "Young PI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1957, "ror": "", "name": "CALLAHAN-YOUNG LLC", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "Social isolation leads to loneliness, which is linked to depression, stress, high blood pressure, and poor sleep, all of which accelerate cognitive decline. The prolonged social isolation that resulted from the COVID-19 pandemic has further highlighted the importance of social connection. Developing new strategies to support AD/ADRD patients and their families is a public health priority, particularly when social and family connections are disrupted. Jigsawdio has created an audiovisual jigsaw puzzle that combines photographs and audio recordings of memories that can be completed alone or with others. Individual pieces are encoded with customized audio recordings that play when the piece is set into place. Our product innovation is driven by several premises. First, according to the Alzheimer’s Society, memory care research shows that even though a person with ADRD may no longer recognize a loved one, their time together has a lasting, positive impact. Second, studies have shown that the emotional state of AD/ADRD patients can be bolstered through nostalgia and reminiscence. Despite being cognitively impaired, people with AD/ADRD experience nostalgia in a manner similar to non-impaired adults. Reminiscence therapy (RT) uses memories and past experiences with tangible prompts, such as photographs or music, to evoke memories and stimulate conversation. For AD/ADRD patients, RT has been shown to have positive effects on quality of life, communication, and mood. Third, opportunities for social experiences that evoke emotional memories can improve mood and decrease agitation in AD/ADRD patients. Fourth, jigsaw puzzles have been shown to reduce stress and agitation. Focusing on a puzzle provides a “breather” from stress and can enhance mood through fun, flow, and mastery. Because of the pandemic, socially engaging activities are desperately needed. Jigsawdio has previously developed a recordable audio puzzle prototype designed for general use. To translate this product for AD/ADRD users, we have assembled a team with expertise in storytelling, nostalgia, AD/ADRD psychology, technology development for AD/RD users, and mental determinants of well-being and happiness. The overall objective of this Phase I STTR proposal is to conduct interviews to create storylines, develop a minimum viable product for AD/ADRD patients, and conduct a usability and acceptability study with participants living in a memory care facility. To achieve these objectives, we will complete the following aims: 1) Conduct in-depth interviews with families, caregivers, and facility staff to collect stories of memorable events and create multiple storylines for each memory care resident. 2) Develop customized audiovisual jigsaw puzzles for memory care residents. The Jigsawdio team will design and engineer an MVP consisting of hardware and software designed for AD/ADRP users. 3) Determine the feasibility and usability of the puzzles for memory care residents. The success of our Phase I project will allow us to refine the Jigsawdio MVP for AD/ADRD users based on user feedback and engage in a large-scale user clinical trial to evaluate the effects of Jigsawdio on emotional well-being, agitation, depression, and anxiety.", "keywords": [ "Address", "Adult", "Adverse event", "Agitation", "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s disease related dementia", "Anxiety", "COVID-19 pandemic", "Caregivers", "Caring", "Clinical Trials", "Cognitive", "Communication", "Custom", "Development", "Disease", "Emotional", "Engineering", "Event", "Exhibits", "Family", "Family Caregiver", "Family member", "Feedback", "Future", "Happiness", "Health", "Health care facility", "Hypertension", "Image", "Impaired cognition", "Indiana", "Individual", "Intervention", "Interview", "Link", "Loneliness", "Memory", "Mental Depression", "Moods", "Music", "Oral", "Participant", "Patient Care", "Patients", "Personal Satisfaction", "Persons", "Phase", "Pilot Projects", "Play", "Psyche structure", "Psychology", "Quality of life", "Recording of previous events", "Reporting", "Research", "Risk Factors", "Small Business Technology Transfer Research", "Social isolation", "Societies", "Software Design", "Stress", "Surveys", "Technology", "Time", "Translating", "Universities", "Visual", "Well in self", "adherence rate", "base", "design", "experience", "improved", "innovation", "interest", "loved ones", "memory care", "mortality risk", "pandemic disease", "poor sleep", "positive emotional state", "prototype", "public health priorities", "recruit", "retention rate", "satisfaction", "social", "success", "technology development", "usability" ], "approved": true } }, { "type": "Grant", "id": "10685", "attributes": { "award_id": "272201700040I-0-759302200006-1", "title": "Task C14: Advancing Human Lung Microphysiological Systems to Model Coronavirus Infection and Test Candidate Countermeasures", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-23", "end_date": "2024-03-22", "award_amount": 1108255, "principal_investigator": { "id": 26740, "first_name": "JENNIFER", "last_name": "YOUNG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 851, "ror": "", "name": "UNIVERSITY OF TEXAS MED BR GALVESTON", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "This contract provides for the development and standardization of difficult-to-source reagents that require the use of nontraditional animal models of infectious diseases.", "keywords": [ "2019-nCoV", "Animal Model", "Basic Science", "COVID test", "Contracts", "Coronavirus Infections", "Development", "Human", "Lung", "Modeling", "Reagent", "Source", "Standardization", "infectious disease model", "microphysiology system" ], "approved": true } }, { "type": "Grant", "id": "10686", "attributes": { "award_id": "1R01MD018548-01A1", "title": "Big Data Digital Outreach and Epidemiology Methods for HIV Care among Communities of Color", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 8046, "first_name": "Nathaniel", "last_name": "Stinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-24", "end_date": "2027-06-30", "award_amount": 811626, "principal_investigator": { "id": 24442, "first_name": "Sean", "last_name": "Young", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 971, "ror": "", "name": "UNIVERSITY OF CALIFORNIA-IRVINE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 971, "ror": "", "name": "UNIVERSITY OF CALIFORNIA-IRVINE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "One of the most significant problems in the field of HIV deals with addressing the low rates of HIV care among individuals living with HIV/AIDS, especially among Black/African American and Latinx communities. This application seeks to study a novel way to address that problem by adopting and applying a cutting-edge “big data outreach” approach being used to increase consumer engagement by top technologies companies. This approach has recently been replacing other digital outreach methods largely for privacy reasons-- to conform to stringent European Union privacy laws-- as it involves de-identified data. The digital outreach method being proposed is already being applied in health (but not yet HIV) settings. During the COVID-19 pandemic, our team and others (including the CDC) studied and found success applying these methods for targeted digital recruitment and outreach to those at high-risk for COVID-19. As a result of the COVID-19 pandemic and its effect on use of digital/remote tools, these approaches will soon be applied to HIV to assist in targeting and engaging hard-to reach individuals in HIV research and care. Importantly, the proposed methods allow access to large-scale passively-collected, opt-in, community and mobility (GPS pings) data, which have been shown to add rich and granular data to improve health surveillance and interventions. This application seeks to use these novel digital outreach methods to identify and enroll individuals living with HIV/AIDS from communities of color who are at high-risk for being out of care, and analyze their mobility and community data to identify the key geographic contexts that impact HIV care engagement. We are conducting this effort for, and in partnership with, 2 Ending the HIV Epidemic (EHE) jurisdictions (Washington D.C. and Orange County health departments) and key participant stakeholders to gain their insights on needs, implementation (including ethical concerns), and potential future scale-up of this approach to improve surveillance and intervention efforts. Specifically, we seek to 1) Identify individuals of color living with HIV/AIDS within EHE regions who are at high-risk for being out of care, 2) Using GPS mobility, community (e.g., local crime), and HIV care data, identify the key geographic contexts that impact HIV care engagement, and 3) In partnership with the Washington D.C. and Orange County health departments, explore a case study of the ongoing barriers and facilitators of this approach at the individual, interpersonal, and structural levels. This 1-year cohort study will be focused on identifying people living within an EHE region who have been hard-to-reach for HIV care in order to converge with EHE outcome measures. To our knowledge, this is the first study to apply these novel “big data outreach” methods to HIV, will enroll the largest cohort to date with GPS mobility, community, and other HIV care contextual data, and the first HIV study to passively collect mobility data, which helps to increase data quality and reduce dropout rates compared to previous studies.", "keywords": [ "AIDS/HIV problem", "Address", "Adherence", "Adopted", "Advertising", "Affect", "African American", "Area", "Big Data", "Black Populations", "Black race", "COVID-19 pandemic", "COVID-19 risk", "Caring", "Case Study", "Centers for Disease Control and Prevention (U.S.)", "Clinic", "Cohort Studies", "Color", "Communication", "Communities", "County", "Crime", "Data", "Data Sources", "Devices", "Dropout", "Enrollment", "Epidemic", "Epidemiologic Methods", "Epidemiology", "Ethics", "European Union", "Facebook", "Future", "Geography", "HIV", "Health", "Health Insurance Portability and Accountability Act", "Home", "Individual", "Intervention", "Interview", "Knowledge", "Latinx", "Latinx population", "Laws", "Learning", "Machine Learning", "Maps", "Marketing", "Mediator of activation protein", "Mental Health", "Methods", "Modeling", "Movement", "Neighborhoods", "Oranges", "Outcome Measure", "Participant", "Pattern", "Persons", "Prevention", "Privacy", "Process", "Public Health", "Research", "Research Personnel", "Risk", "Sampling", "Services", "Structure", "Surveys", "Target Populations", "Technology", "Time", "United States", "Visualization", "Washington", "aged", "barrier to care", "base", "care outcomes", "cohort", "data de-identification", "data quality", "design", "digital", "digital communication", "experience", "follow-up", "handheld mobile device", "high risk", "implementation science", "improved", "innovation", "insight", "mobility aid", "multilevel analysis", "novel", "outreach", "people of color", "public-private partnership", "recruit", "scale up", "socioeconomics", "success", "tool" ], "approved": true } }, { "type": "Grant", "id": "10687", "attributes": { "award_id": "1R43GH002390-01A1", "title": "Pan-COVID Therapeutic", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2023-03-29", "award_amount": 275766, "principal_investigator": { "id": 26741, "first_name": "JAMES W", "last_name": "LARRICK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26742, "first_name": "Bo", "last_name": "Yu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1958, "ror": "", "name": "LARIX BIOSCIENCE, LLC", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Pan-COVID Therapeutic Abstract Severe COVID-19 remains as an urgent unmet clinical need for unvaccinated people, particularly as the SARS- CoV-2 delta and omicron variants spread globally. Despite the rapid deployment of effective vaccines, a large percentage of Americans are not fully vaccinated. About 15% of COVID-19 patients require hospitalization with 5% requiring intensive care, among whom nearly half of patients succumb to the disease without an effective therapeutic option. Because angiotensin-converting enzyme 2 (ACE2) is the cell surface receptor of the SARS- CoV-2 spike (S) glycoprotein for cell entry, soluble ACE2 has been used as a decoy receptor to inhibit SARS- CoV-2 infection in vitro and in vivo. However, the affinity of the wild type human ACE2 is not high enough (tens of nM) to warrant therapeutic development. We have generated a high affinity ACE2 (>100-fold). This engineered ACE2 will be effective against all variants, including delta. Fusion of this engineered ACE2 to a human immunoglobulin Fc region is expected to result in superior pharmacokinetics, as Fc will confer a long circulating half-life and the ability to be delivered to airway mucosal surfaces, the primary site of SARS-CoV-2 infection. Unlike anti-SARS-CoV-2 antibodies, the ACE2-Fc decoy fusion protein will not subject the virus to selection for neutralization escape mutants, as any mutation that decreases binding to the decoy will reduce binding to the native receptor, resulting in an attenuated virus. Our engineered ACE2 maintains the peptidase activity that decreases angiotensin II (Ang II) concentration to alleviate AGTR1/AGTR2-mediated vasoconstriction that exacerbates the acute respiratory distress. The active ACE2-Fc will address the underlining pathogenesis of severe COVID-19 in addition to blocking the viral entry, and provides superior efficacy versus neutralizing antibodies. During this Phase 1 project, we will engineer an active ACE2 with >100-fold affinity improvement to the SARS-CoV-2 spike protein, and fuse it to a human Fc. The resulting decoy fusion protein will inhibit viral binding to its receptor ACE2 as well as locally target the renin–angiotensin system (RAS) to attenuate severe respiratory distress. The outcome of this work will be a novel best-in-class therapy for SARS-CoV-2 and potentially other viral acute respiratory distress syndromes.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10688", "attributes": { "award_id": "75N95021D00029-0-759502200003-1", "title": "SECURE PLATFORMS SUPPORT FOR THE N3C DATA ENCLAVE (COVID-19)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)", "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-25", "end_date": "2022-12-17", "award_amount": 4225000, "principal_investigator": { "id": 26481, "first_name": "BRIAN", "last_name": "ZAVERTNIK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1737, "ror": "", "name": "PALANTIR TECHNOLOGIES, INC.", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, https://covid.cd2h.org/, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C Data Enclave is a secure platform storing harmonized clinical data provided by more than 60 contributing members. The Enclave hosts over 670 million clinical observations on over 6.8 million persons, including over 2.2 million COVID cases, amounting to more than 7.8 billion rows of data. To protect privacy, this data consists only of limited data sets, de-identified data sets, and synthetic data sets; there is no personally identifiable information kept in the Enclave. The Enclave resides in the NCATS Secure Scientific Platforms Environment. The Environment is a specialized cloud-based data aggregation and analytics enclave that can integrate, manage, secure, and analyze any kind of scientific data, and provide secure, controlled access to internal and external collaborators. Within the Environment, multiple NIH ICs, Federal agencies, and Federal task forces integrate, manage, secure, and analyze all types of scientific data using dedicated platforms, and, equally importantly, make that data available in specific and controlled collaborations with each other and with external collaborators.", "keywords": [ "Advisory Committees", "Award", "COVID-19", "Clinical", "Clinical Data", "Clinical Research", "Clinical and Translational Science Awards", "Collaborations", "Data", "Data Aggregation", "Data Analytics", "Data Set", "Development", "Environment", "Health", "National Center for Advancing Translational Sciences", "National Institute of General Medical Sciences", "Personally Identifiable Information", "Persons", "Privacy", "Research", "Secure", "Translational Research", "United States National Institutes of Health", "cloud based", "cohort", "coronavirus disease", "data de-identification", "data enclave", "member", "programs" ], "approved": true } }, { "type": "Grant", "id": "10689", "attributes": { "award_id": "1R21HL165406-01", "title": "Dissecting SARS-CoV-2 infection in Down syndrome with congenital heart defects using patient-specific iPSCs", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 23077, "first_name": "Charlene A.", "last_name": "Schramm", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-06", "end_date": "2024-07-31", "award_amount": 234000, "principal_investigator": { "id": 26743, "first_name": "Mingtao", "last_name": "Zhao", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 879, "ror": "", "name": "RESEARCH INST NATIONWIDE CHILDREN'S HOSP", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "Down syndrome (DS) is the most common genetic disorder occurring in about 1 in 800 live births, and is characterized by a distinctive facial appearance, intellectual disability, and developmental delays. Gene dosage imbalance in DS patients, primarily caused by an extra copy of chromosome 21 (trisomy 21), is thought to contribute to a broad spectrum of coexisting medical conditions. DS is frequently associated with congenital heart defects (CHDs); approximately 40% of DS patients have some form of CHD, with atrioventricular septal defects (AVSD) being the most prevalent. The swift global spread of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the ongoing pandemic. Intriguingly, DS patients are more vulnerable to SARS-CoV-2 infection: there is a 4-fold increased risk for COVID- 19-related hospitalization and a 10-fold higher risk for COVID-19-related death compared to patients without DS. Mechanisms by which individuals with DS are more susceptible to COVID-19 are largely unknown. Genetically engineered mice made trisomic for homologous chromosome 16 (MMU16) were developed to study genotype- phenotype correlations in DS. However, because authentic SARS-CoV-2 is unable to infect mice due to the inefficient interaction between the viral S-protein and the mouse orthologue of its receptor, human angiotensin converting enzyme 2 (ACE2), it is not ideal to recapitulate SARS-CoV-2 infection in DS patients using current DS mouse models. In this R21 proposal, we aim to bridge this knowledge gap by dissecting the mechanistic causes of the susceptibility of DS patients to COVID-19 using patient-specific induced pluripotent stem cells (iPSCs). Some genes encoded by chromosome 21 (e.g. transmembrane proteinase serine 2, TMPRSS2) are dysregulated in individuals with DS and have been implicated to have a role in SARS-CoV-2 infection. Our central hypothesis is that upregulation of TMPRSS2 in DS leads to enhanced SARS-CoV-2 infection in the lungs, resulting in an enhanced cytokine surge that increases the severity of COVID-19. In Specific Aim 1, we will elucidate the mechanisms underlying the enhanced cytokine surge in Down syndrome in response to SARS- CoV-2 infection using DS iPSC-derived lung organoids. In Specific Aim 2, we will determine the gene-dosage effect of TMPRSS2 on SARS-CoV-2 infection in DS iPSC-derived cardiac and endothelial cells. It is expected that this project will have a major impact on the understanding of susceptibility of DS patients to SARS-CoV-2 infection using clinically relevant and patient-specific cardiac and lung cells.", "keywords": [ "2019-nCoV", "ACE2", "Alveolar", "Appearance", "Binding", "Biological Assay", "COVID-19", "COVID-19 mortality", "COVID-19 pandemic", "COVID-19 patient", "COVID-19 risk", "COVID-19 severity", "COVID-19 susceptibility", "Cardiac", "Cardiac Myocytes", "Cardiovascular system", "Cell Line", "Cell membrane", "Cell surface", "Cells", "Chromosome 16", "Chromosome 21", "Chronic", "Congenital Heart Defects", "Developmental Delay Disorders", "Down Syndrome", "Endothelial Cells", "Face", "Gene Dosage", "Genes", "Genetic", "Genetic Diseases", "Genetic Materials", "Genetically Engineered Mouse", "Genotype", "Heart", "Hospitalization", "Human", "Immune", "Incubated", "Individual", "Infection", "Integral Membrane Protein", "Intellectual functioning disability", "Knowledge", "Lead", "Live Birth", "Lung", "Medical", "Membrane", "Membrane Fusion", "Mus", "Organ", "Organoids", "Patients", "Pediatric cardiology", "Phenotype", "Predisposition", "Proteins", "RNA Viruses", "Role", "SARS-CoV-2 infection", "Serine Protease", "Serum", "Testing", "Therapeutic", "Tissues", "Transgenic Mice", "Up-Regulation", "Viral", "Virion", "atrioventricular septal defect", "clinically relevant", "cytokine", "high risk", "induced pluripotent stem cell", "induced pluripotent stem cell derived cardiomyocytes", "mouse model", "multidisciplinary", "novel", "pandemic disease", "pathogen", "receptor", "response", "single-cell RNA sequencing", "stem cell biology", "virology" ], "approved": true } }, { "type": "Grant", "id": "10690", "attributes": { "award_id": "1R01GM146962-01", "title": "Four-dimensional Adhesion Frequency Assay for Full Profiling of Receptor-ligand Interactions on Cells", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 23422, "first_name": "ALVIN TIEN-WEI", "last_name": "Yeh", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-21", "end_date": "2026-08-31", "award_amount": 379952, "principal_investigator": { "id": 26744, "first_name": "Yuebing", "last_name": "Zheng", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 972, "ror": "", "name": "UNIVERSITY OF TEXAS AT AUSTIN", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "This R01 application is responsive to the NIH initiative PAR-19-253 “Focused Technology Research and Development”. Assays for measuring receptor-ligand affinity are valuable in many areas of biomedical research. The “gold standard” surface plasmon resonance assay is limited to recombinant soluble receptors fixed on solid surfaces. The emerging adhesion frequency assay (AFA) techniques can measure the receptor-ligand affinity on their native cellular membranes. However, existing AFA methods can neither resolve the non-uniform distribution of receptors on single cells nor measure the rolling cell adhesion under shear forces. In addition, currentAFAapproaches are generally bulky and low throughput, which require tedious operation. Recently, we have invented a light-driven microrobot (LDM) platform as a non-invasive, programmable, and multimodal cell-manipulation technology. Based on this versatile LDM platform, we propose to develop a paradigm- shift four-dimensional (4D) AFA (i.e., integrated 3D translational AFA and 3D rotational AFA) to overcome these key obstacles in the existing assays. In this R01 project, we will develop and validate our 4D AFA with the following features: (1) measuring receptors on their native cell membrane environments, (2) resolving the non-uniformly distributed receptors on single cells, (3) enabling both translational and rotational AFAs on an integrated platform, (4) investigating cell adhesion under both shear force and tensile force, and (5) allowing on-chip multiplexed cell adhesion measurements. With such features, the proposed 4D AFA has the potential to exceed current lab standards, address unmet needs in the field, and enable high-throughput full profiling of receptor-ligand interactions at sub-cellular resolution. We will validate and improve the 4D AFA performance using well-studied receptor-ligand pairs with variable affinities. We will further package and apply the validated assay to investigate the binding of SARS-CoV-2 virus to angiotensin-converting enzyme 2 receptor and to screen T cells for immunotherapy for cytomegalovirus infection. In this regard, we aim to demonstrate the far-reaching potential of 4D AFA to enable improved research in areas ranging from clinical immunotherapy to fundamental biology.", "keywords": [ "2019-nCoV", "3-Dimensional", "ACE2", "Address", "Adhesions", "Affinity", "Anti-Bacterial Agents", "Antiviral Agents", "Area", "Automation", "Bacterial Infections", "Benchmarking", "Binding", "Biological", "Biological Assay", "Biological Process", "Biology", "Biomedical Research", "Biometry", "Biophotonics", "CD8-Positive T-Lymphocytes", "Cell Adhesion", "Cell membrane", "Cell surface", "Cells", "Cellular Membrane", "Cellular biology", "Clinical", "Complex", "Custom", "Cytomegalovirus Infections", "Devices", "Endothelium", "Environment", "Epithelial Cells", "Event", "Four-dimensional", "Frequencies", "Glycoproteins", "Goals", "Gold", "Hematopoietic", "Human body", "Immunity", "Immunotherapy", "Infection", "Kinetics", "Lasers", "Ligands", "Light", "Major Histocompatibility Complex", "Maps", "Measurement", "Measures", "Methods", "Microfluidics", "Modality", "Optics", "Peptides", "Performance", "Pharmaceutical Preparations", "Process", "Production", "Recombinants", "Research", "Research Personnel", "Resolution", "Rotation", "Site", "Solid", "Stress", "Surface", "Surface Plasmon Resonance", "System", "T-Cell Receptor", "T-Lymphocyte", "Techniques", "Technology", "Translations", "United States National Institutes of Health", "Virus", "Virus Diseases", "austin", "base", "biomaterial compatibility", "cancer cell", "cell killing", "clinical application", "community clinic", "design", "digital", "experimental study", "imaging system", "improved", "insight", "medical schools", "microrobot", "microsystems", "multimodality", "multiplex assay", "novel", "operation", "optical imaging", "pathogen", "programs", "prototype", "receptor", "recruit", "shear stress", "simulation", "technology research and development", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "10691", "attributes": { "award_id": "1R21AR081655-01", "title": "Pathogenesis of myalgia and fatigue after SARS-CoV-2 infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 26745, "first_name": "Emily Foran", "last_name": "Carifi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-23", "end_date": "2024-08-31", "award_amount": 270903, "principal_investigator": { "id": 26746, "first_name": "Sachiko", "last_name": "Homma", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26747, "first_name": "Lan", "last_name": "Zhou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 860, "ror": "", "name": "BOSTON UNIVERSITY MEDICAL CAMPUS", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "As the COVID-19 pandemic continues, managing post COVID-19 long-haul symptoms have become the next level challenge. Persistent skeletal muscle aches (myalgia) and fatigue are among the most common symptoms reported by COVID-19 long haulers who have symptoms beyond 20 weeks. The myalgia associated with COVID-19 often responds poorly to pain medications. The long-COVID symptoms, especially myalgia, fatigue, dyspnea, and brain fog, significantly affect the quality of life and employment status of COVID-19 long haulers. Although myalgia and fatigue are common during acute respiratory viral infection, the muscle symptoms caused by SARS-CoV-2 often last much longer than other respiratory viral infections including influenza. The pathogenic mechanisms underlying the development and persistence of myalgia and fatigue associated with COVID-19, however, is largely unknown, which makes the treatment difficult. We thus propose this R21 study to explore the mechanisms. There are four potential mechanisms, including direct viral invasion to skeletal muscle, ischemic muscle injury from microthrombi and cardiopulmonary dysfunction, immune- mediated muscle damage caused by an exuberant systemic inflammatory response, and altered muscle energy homeostasis. We propose to address these mechanisms by conducting an exploratory longitudinal study to characterize the skeletal muscle response to respiratory SARS-CoV-2 infection to determine how skeletal muscle is affected at the histopathological level and transcriptional level during and after acute infection, and whether the muscle responses to SARS-CoV-2 and influenza A (IAV) viral infections are different. By using muscle tissues collected from SARS-CoV-2-infected golden hamsters, one of the best small animal models for COVID-19, our preliminary study found no detectable SARS-CoV-2 nucleocapsid protein or inflammation to suggest direct viral invasion to muscle. There were no microthrombi either. These findings lead to our central hypothesis that myalgia and fatigue associated with COVID-19 are likely caused by altered muscle energy metabolism due to a systemic inflammatory response and hypoxia during acute SARS-CoV-2 infection, followed by a prolonged recovery course. This hypothesis will be addressed by two specific aims. Aim 1 will identify muscle histopathological changes at different stages after SARS-CoV-2 infection and compare with IAV infection. Aim 2 will characterize the muscle transcriptional response to SARS-CoV-2 infection and the dynamic transcriptional changes with time. We will also compare SARS-CoV-2 infection with IAV infection to address whether the recovery of the initial skeletal muscle response to SARS-CoV-2 infection is slower. Our study will likely identify histopathological features and transcriptional signatures that may underlie myalgia and fatigue associated with COVID-19. The mechanisms uncovered will help guide therapies.", "keywords": [ "2019-nCoV", "ACE2", "Acute", "Address", "Affect", "Analgesics", "Animal Model", "Animals", "Atrophic", "Body Weight decreased", "COVID-19", "COVID-19 detection", "COVID-19 long hauler", "COVID-19 pandemic", "Cardiopulmonary", "Chronic", "Cytokine Gene", "Development", "Dyspnea", "Employment Status", "Energy Metabolism", "Environment", "Enzymes", "Fatigue", "Functional disorder", "Gene Expression", "Gene Expression Profile", "Gene Expression Profiling", "Genes", "Genetic Transcription", "Glucose", "Hamsters", "Heart", "Homeostasis", "Hypoxia", "Immune", "Immune response", "Individual", "Infection", "Inflammation", "Inflammatory", "Influenza", "Influenza A virus", "Injury", "Interferons", "Intranasal Administration", "Invaded", "Ischemia", "Lead", "Locomotion", "Long COVID", "Longitudinal Studies", "Lung", "Mediating", "Mesocricetus auratus", "Mitochondria", "Modeling", "Muscle", "Muscle Fatigue", "Muscle Fibers", "Muscle Mitochondria", "Muscular Atrophy", "Myalgia", "Myocardial Infarction", "Nucleocapsid Proteins", "Oxygen", "Pathogenesis", "Pathogenicity", "Pathologic", "Pathology", "Patients", "Phase", "Production", "Publishing", "Pulmonary Embolism", "Quality of life", "Recovery", "Regulator Genes", "Reporting", "Research", "Research Personnel", "SARS-CoV-2 infection", "Signal Pathway", "Skeletal Muscle", "Stroke", "Symptoms", "Thrombosis", "Time", "Up-Regulation", "Viral", "Viral Respiratory Tract Infection", "Virus", "Virus Diseases", "acute infection", "anaerobic glycolysis", "base", "brain fog", "common symptom", "cytokine", "disabling symptom", "experience", "fatty acid metabolism", "mRNA Expression", "muscle regeneration", "post SARS-CoV-2 infection", "post-COVID-19", "receptor", "respiratory", "response", "systemic inflammatory response", "tissue injury", "transcriptome sequencing", "transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "10692", "attributes": { "award_id": "1U01IP001184-01", "title": "RFA-IP-22-004, Evaluating respiratory virus vaccine effectiveness in a large, diverse healthcare system", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2027-09-30", "award_amount": 2495017, "principal_investigator": { "id": 26748, "first_name": "RICHARD K", "last_name": "ZIMMERMAN", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "– Component A We are applying for RFA components A and D. This abstract refers to Component A. Influenza/pneumonia comprise the 9th and COVID-19 the 3rd leading cause of death in the U.S., with the pandemic entering its 3rd year. Vaccine effectiveness (VE) estimates vary by host factors, viral clade, match to circulating virus, time since vaccination (i.e., waning) and specific vaccine characteristics. PittVax and collaborators have been integral to the US Flu VE Network for 12 years, contributing to influ- enza and COVID-19 VE estimates. Among the current 7 Network sites, PittVax ranks #2 in enrollments, #2 in bloodspot collections, and #1 in follow-up survey completion, while exceeding enrollment goals. PittVax has published >300 peer-reviewed articles in the field. We propose a test-negative case-control design (TND) study among UPMC and federally qualified health center (FQHC) outpatients to determine influenza, COVID-19 and possibly, other respiratory virus VE. Our specific aims are: 1) Determine VE against laboratory-confirmed, medically-attended, acute respiratory in- fections among 1000-1200 outpatients during the influenza season in age groups: 6 mos-18 yrs, 19-49 yrs, and ≥50 yrs, using test negative design in onsite enrollment during respiratory season plus remote enroll- ment outside of influenza season (another 400-900 if COVID-19 persists); 2) provide genetic sequencing on selected specimens for biweekly trends in clade; and 3) determine the annual, population-based burden of influenza and COVID-19 for Allegheny County (Pittsburgh) from the UPMC Health Plan. For determining prior infection for SARS-CoV-2 (e.g., N protein) in the highest proportion of participants, we propose finger- stick bloodspots, supplemented by sera on a subset, for more in-depth studies. The Williams lab, using vali- dated 96-well plate instruments for RT-PCR, which analyzed >10,000 specimens over the last 6 years for influenza, SARS-CoV-2 and other respiratory viruses, will determine presence of infecting viruses. The ex- perienced Harrison lab will perform viral genomic sequencing. We will obtain immunization records from the state’s registry and from UPMC’s and the FQHC’s electronic records. UPMC Health Plan is the largest insurer in Allegheny County and at UPMC in 2021-22, >126,000 county residents were clinically tested for SARS-CoV-2. Annually, UPMC records >5.6 million outpatient visits. Over 1.4 million UPMC acute care visits a year are assessed at Emergency Departments (EDs) and Urgent Care clinics through a common structure and e-record with 305,751 ED visits in 2021 among our four recruiting EDs. UPMC has been rated one of the most wired health systems for 23 years. To address health equity, we add FQHC offices serving mostly persons of color and leadership from the Black Equity Coalition to our multidisciplinary team to assist with culturally competent script/survey development, inclusion of social deter- minants of health data and dissemination of findings with a health equity perspective.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10693", "attributes": { "award_id": "1R41HD111097-01", "title": "FASTT telehealth behavioral support service for caregivers of children with developmental delay or disability", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 21350, "first_name": "Sujata", "last_name": "Bardhan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-23", "end_date": "2023-08-31", "award_amount": 252262, "principal_investigator": { "id": 26749, "first_name": "Shannon", "last_name": "Peake", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26750, "first_name": "Stephen John", "last_name": "Zimmerman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1959, "ror": "", "name": "SPECIAL X INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Over 7 million children in the U.S. receive support for a developmental delay or disability (DD). For caregivers of these children, behavior issues that often accompany their child's condition create high levels of stress leading to increased mental and physical health issues and impacts on caregiver-child interactions and family functioning. Although evidence-based practices exist to help caregivers with their child's behavioral development, access to these services is often limited by rigid delivery models requiring in-person visits that can delay support and further increase the burden on families. These barriers are disproportionately higher for families of color and for those in low resource situations: an effect that has been exacerbated by reductions in services due to COVID-19. The overall objective of this project is to develop and implement a telehealth delivery model of rapid-response, evidence-based behavioral support to be provided in conjunction with an existing family navigation program (Undivided) serving parents of children with DD to create a commercially marketable product that will reduce barriers to services in local communities across the country. Building on Undivided's established systems and trusted relationships with a large community of families of children with DD, this project will extend that support by partnering with a text and telephone support service for caregivers of young children (FASTT). This Phase 1 application will enable a collaborative process to adapt evidence- based behavioral support to the specific needs of families of children ages birth to 12 with DD and integrate that support within the existing family navigation service. The rationale for the work is that providing effective, personalized support through the widely accessible mediums of text and telephone will get caregivers the help they need when and where they have time to access it and close in time to the behavioral issues they need help with, thus reducing caregiver stress and increasing their sense of competence and positive interactions with their child. Aim 1 determines the feasibility of delivering evidence-based behavioral support to caregivers of children with disabilities using on-demand text messaging. Aim 2 gauges the acceptability of the text-based support service to caregivers. Aim 3 assesses the extent to which text-based support reduces caregiver stress, improves caregiver sense of competence, and builds more positive perceptions of their child's behavior and their relationship with their child. The positive impacts of the project are twofold. First, the integration of the Undivided support platform with FASTT behavioral support represents an innovative approach to addressing the critical gap in early intervention services for caregivers of children with DD with significant immediate and long-term benefits for those families. Second, creating a delivery model that enables family navigation services to provide evidence-based telehealth behavioral support as part of their service portfolio will create marketable value by increasing engagement with families and subsequently increasing potential subscription revenue.", "keywords": [ "Address", "Age", "Appointment", "Attention deficit hyperactivity disorder", "Behavior", "Behavior Disorders", "Behavioral", "Birth", "COVID-19", "Caregiver support", "Caregiver well-being", "Caregivers", "Caring", "Cerebral Palsy", "Child", "Child Behavior", "Child Care", "Child Development", "Clinic", "Clinical", "Collaborations", "Color", "Communities", "Competence", "Country", "Custom", "Development", "Developmental Delay Disorders", "Developmental Disabilities", "Diagnosis", "Disabled Children", "Early Intervention", "Economics", "Ethnic Origin", "Evidence based practice", "Familiarity", "Family", "Genetic Diseases", "Health Services Accessibility", "Hearing problem", "Home", "Improve Access", "Infrastructure", "Internet", "Lead", "Learning Disorders", "Length", "Location", "Mental Health", "Methods", "Modeling", "Other Genetics", "Parents", "Perception", "Persons", "Phase", "Positioning Attribute", "Positive Reinforcements", "Problem behavior", "Process", "Provider", "Race", "Reporting", "Resources", "Secure", "Services", "Social Behavior", "Socioeconomic Status", "Stress", "Structure", "Supervision", "System", "Technology", "Text", "Text Messaging", "Text Telephone", "Time", "Training", "Transportation", "Travel", "Trust", "Videoconferencing", "Vision Disorders", "Visit", "Work", "autism spectrum disorder", "base", "care coordination", "caregiver stress", "cost", "disability", "emotional behavior", "evidence base", "experience", "family burden", "family support", "flexibility", "improved", "innovation", "knowledgebase", "physical conditioning", "programs", "public health priorities", "racial and ethnic", "response", "screening", "service delivery", "service intervention", "skills", "stress management", "telehealth", "texting support" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1442, "count": 14420 } } }